Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Investment Tools And Research To Help Make You A More Confident And Profitable Trader. FREE 30 Day Trial

Stocks | Futures | Watchlist | More
or

Artelo Biosciences Inc (ARTL)

Artelo Biosciences Inc (ARTL)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 8,767
  • Shares Outstanding, K 2,856
  • Annual Sales, $ 0 K
  • Annual Income, $ -7,440 K
  • 60-Month Beta 1.37
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 0.40
Trade ARTL with:

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 3 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/22
See More
  • Average Estimate -0.87
  • Number of Estimates 1
  • High Estimate -0.87
  • Low Estimate -0.87
  • Prior Year -1.20
  • Growth Rate Est. (year over year) +27.50%

Price Performance

See More
Period Period Low Period High Performance
1-Month
2.91 +5.15%
on 02/02/23
3.50 -12.57%
on 01/18/23
-0.08 (-2.55%)
since 01/06/23
3-Month
2.38 +28.57%
on 11/22/22
3.50 -12.57%
on 01/18/23
+0.34 (+12.50%)
since 11/04/22
52-Week
2.38 +28.57%
on 11/22/22
11.07 -72.37%
on 04/13/22
-3.09 (-50.24%)
since 02/04/22

Most Recent Stories

More News
Artelo's (ARTL) FABP5 Inhibitor Effective in Pre-Clinical Study

Artelo Biosciences (ARTL) reports positive pre-clinical data from one of its FABP5 inhibitors in anxiety-related disorders. Stock up.

STRO : 6.87 (-3.38%)
ARTL : 3.06 (-0.33%)
IMVT : 18.41 (+3.72%)
INZY : 2.77 (-3.15%)
Artelo Biosciences Reports Second Quarter 2022 Financial Results and Provides Business Update

CAReS Study Evaluating ART27.13 in Cancer Anorexia Progresses to Fourth Cohort ART26.12 Program to Target Chemotherapy-Induced Peripheral Neuropathy ...

ARTL : 3.06 (-0.33%)
Artelo Biosciences Completes Enrollment of the First Three Cohorts in its CAReS Study Evaluating ART27.13 for the Treatment of Cancer-Related Anorexia and Weight Loss

Initiates Fourth Cohort at a 650-Microgram Dose with Data Expected in Q4 2022 ...

ARTL : 3.06 (-0.33%)
Artelo Biosciences Presents Positive Pre-Clinical Results of ART26.12, a Novel FABP5 Inhibitor, in Alleviating Chemotherapy-Induced Pain

Presentation delivered by Professor Saoirse O’Sullivan at the 32nd Annual ICRS Symposium in Galway, Ireland on Sunday, June 26th...

ARTL : 3.06 (-0.33%)
Artelo Biosciences Presents Positive Pre-Clinical Results of ART26.12, a Novel FABP5 Inhibitor, in Alleviating Chemotherapy-Induced Pain

Presentation delivered by Professor Saoirse O’Sullivan at the 32nd Annual ICRS Symposium in Galway, Ireland on Sunday, June 26th...

ARTL : 3.06 (-0.33%)
Artelo Biosciences Selected for Oral Presentation at the 32nd Annual ICRS Symposium in Galway, Ireland

SOLANA BEACH, Calif., June 24, 2022 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (Nasdaq: ARTL), a clinical-stage pharmaceutical company focused on...

ARTL : 3.06 (-0.33%)
Artelo Biosciences to Present at the LD Micro Invitational XII on June 7th

SOLANA BEACH, Calif., June 01, 2022 (GLOBE NEWSWIRE) --  Artelo Biosciences, Inc. “Artelo” or the “Company”) (NASDAQ: ARTL), a clinical-stage...

ARTL : 3.06 (-0.33%)
36 of the Best Ideas Companies to Present at the Spring into Action - Best Ideas Investor Conference on May 16th - 20th, 2022

RALEIGH, NC / ACCESSWIRE / May 16, 2022 / The Spring into Action- Best Ideas Virtual Investor Conference will take place on May 16th - 20th, 2022, where 36 SmallCap, MicroCap and NanoCap public companies...

ACST : 0.7090 (+3.50%)
LPTH : 1.5500 (-0.64%)
RCAT : 1.4100 (+20.51%)
IONM : 0.2965 (+3.53%)
PYR : 1.1300 (+9.87%)
OSS : 3.55 (+1.10%)
MODD : 2.35 (-7.11%)
STRN : 1.3400 (+0.75%)
AEYE : 6.74 (+13.28%)
SMFL : 0.2101 (+5.00%)
LFMD : 2.16 (-2.92%)
SURG : 6.20 (-1.43%)
Artelo Biosciences to Present at the H.C. Wainwright Global Investment Conference on May 24th

SOLANA BEACH, Calif., May 16, 2022 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. “Artelo” or the “Company”) (NASDAQ: ARTL), a clinical stage...

ARTL : 3.06 (-0.33%)
Artelo Biosciences to Present at MicroCap Rodeo’s Spring into Action Best Ideas Virtual Conference on May 16th

SOLANA BEACH, CA / ACCESSWIRE / May 13, 2022 / Artelo Biosciences, Inc. "Artelo" or the "Company") (NASDAQ:ARTL), a clinical stage pharmaceutical company developing therapeutics that modulate lipid-signaling...

ARTL : 3.06 (-0.33%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 24% Sell with a Weakest short term outlook on maintaining the current direction.

See More Share

Business Summary

Artelo Biosciences Inc. is a biopharmaceutical company. It is engaged in development and commercialization of proprietary therapeutics targeting the endocannabinoid system. The company's product pipeline consists of ART27.13, ART12.11 and ART26.12 which are in clinical stage. Artelo Biosciences Inc....

See More

Key Turning Points

3rd Resistance Point 3.23
2nd Resistance Point 3.15
1st Resistance Point 3.11
Last Price 3.06
1st Support Level 2.98
2nd Support Level 2.90
3rd Support Level 2.86

See More

52-Week High 11.07
Fibonacci 61.8% 7.75
Fibonacci 50% 6.73
Fibonacci 38.2% 5.70
Last Price 3.06
52-Week Low 2.38

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar